No drugs aimed specifically at cancers with PIK3CA mutations have been approved by the FDA to date, although several PI3K agents targeting the PIK3CA gene product, targeting PI3Kα, have entered into Phase 1 clinical trials [4] including BYL719 (Novartis) and GDC-0032 (Genentech). This evidence concerns the gene PIK3CA and cancer.